George Degner
Internal Medicine · Stayton, ORNPI 1700923406
Payments from drug & device makers
Across 122 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$310
- Amgen$296
- AstraZeneca$286
- Novo Nordisk$234
- Sanofi$117
- United Therapeutics Corporation$104
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,38897%
- Education$703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $310 |
| Amgen(2 entities) | 13 | $296 |
| AstraZeneca | 15 | $286 |
| Novo Nordisk | 12 | $234 |
| Sanofi | 7 | $117 |
| United Therapeutics Corporation | 5 | $104 |
| Sanofi-aventis U.S. LLC | 7 | $103 |
| Exact Sciences | 4 | $95 |
| Johnson & Johnson | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| GSK | 4 | $79 |
| Bayer | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Philips North America LLC | 3 | $45 |
| Mylan Specialty L.p. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Lilly USA, LLC | 1 | $31 |
| Amarin Pharma, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $23 |
| Electromed, Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Novartis | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$2,458 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 197 | $169,880 |
| JardianceEmpagliflozin | 72 | $86,345 |
| TrulicityDulaglutide | 52 | $73,911 |
| FarxigaDapagliflozin Propanediol | 83 | $65,964 |
| OzempicSemaglutide | 47 | $47,922 |
| MounjaroTirzepatide | 40 | $44,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $37,148 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $24,144 |
| Humalog Kwikpen U-100Insulin Lispro | 37 | $20,937 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $20,108 |
| XareltoRivaroxaban | 19 | $18,237 |
| InvokanaCanagliflozin | 11 | $12,151 |
| JanuviaSitagliptin Phosphate | 13 | $6,987 |
| Gabapentin | 232 | $5,298 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $310 | $169,880197 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $31 | $118,27992 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $15 | $91,49983 claims |
| AstraZenecaFarxiga | $286 | $65,96483 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $79 | $61,29286 claims |
| Novo NordiskOzempic | $234 | $47,92247 claims |
| Johnson & JohnsonXarelto, Invokana | $81 | $30,38830 claims |
| MerckJanuvia | $22 | $6,98713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Stayton
- Michael ChenStayton$1.2M
- Stephen SpurgeonPortland$8.6M
- Drissana TranSalem$4.8M
- James BergtholdPortland$4.7M
- Stephen FortmannPortland$3.3M
- Maryann ConradPortland$2.7M
- Brian CurtisCorvallis$2.4M
- Jennifer SaultzPortland$1.9M
- Elizabeth LilesHillsboro$1.9M
- Marc UemuraEugene$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.